|
Mar 14
|
Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month
|
|
Feb 25
|
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 25
|
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
|
|
Feb 20
|
These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts
|
|
Feb 18
|
Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan
|
|
Feb 18
|
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
|
|
Feb 18
|
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
|
|
Feb 15
|
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
|
|
Oct 2
|
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
|
|
Aug 28
|
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
|
|
Aug 27
|
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
|
|
Aug 16
|
Nuntius partners with Taiho to develop mRNA cancer therapies
|
|
Aug 8
|
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
|
|
Aug 7
|
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 5
|
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 25
|
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
|
|
Jun 2
|
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
|
|
Jun 1
|
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
|
|
May 31
|
It's Unlikely That Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Will See A Huge Pay Rise This Year
|